Oral glucose loading for detection of mitochondrial toxicity during HAART in HIV-infected patients

Current HIV Research

Volumn 5, Issue 4, 2007, Pages 389-393

  ter Hofstede, Hadewych J M ^a   Borm, George F ^a   Koopmans, Peter P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV infection; Lactate; Mitochondrial toxicity; NRTI; Nucleoside reverse transcriptase inhibitors; OGTT

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; GLUCOSE; INDINAVIR; LACTIC ACID; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY LIVER; FEMALE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; MALE; MITOCHONDRIAL TOXICITY; NEUROPATHY; ORAL GLUCOSE TOLERANCE TEST; REVIEW; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG TOXICITY; FEMALE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS; ROC CURVE;

EID: 34447274512     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207781023983     Document Type: Review

References (45)

1. Becker S. (2004). Liver toxicity in epidemiological cohorts. Clinical Infectious Diseases. 38: S49-S55.
2. Bergman RN, Ader M. (2000). Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinology and Metabolism. 11: 351-356.
3. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cone L, Chevallier M, Bernuau J, Lucet JC, Trepo C. (1994). Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. Journal of Internal Medicine. 235: 367-371.
4. Blanco F, Carr A. (2004). Lipodystrophy syndrome: Diagnostic, clinic and therapeutic aspects. AIDS Reviews. 3: 98-105.
5. Boles RG, Chun N, Senadheera D, Wong L.J. (1997). Cyclic vomiting syndrome and mitochondrial DNA mutations. Lancet. 350: 1299-1300.
6. Brew BJ, Tisch S, Law M. (2003). Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS. 17: 1094-1096.
7. Brinkman K. (2000). Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clinical Infectious Diseases. 31: 167-169.
8. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. (1998). Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 12: 1735-1744.
9. Carr A. (2000). HIV protease inhibitor-related lipodystrophy syndrome. Clinical Infectious Diseases. 30: S135-S142.
10. Carr A, Cooper DA. (2000). Adverse effects of antiretroviral therapy. Lancet. 356: 1423-1430.
11. Carr A, Law M. (2003). An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. Journal of Acquired Immune Deficiency Syndrome. 33: 571-576.
12. Carr A, Miller J, Law M, Cooper D A. (2000). A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 14: F25-F32.
13. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12: F51-F58.
14. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 353: 2093-2099.
15. Chariot P, Monnet I, Mouchet M, Rohr M, Lefaucheur JP, Dobreuil-Lemaire ML, Chousterman M, Gherardi R. (1994). Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis and Rheumatism. 37: 583-586.
16. Chi CS, Mak SC, Shian WJ, Chen CH. (1992). Oral glucose lactate stimulation test in mitochondrial disease. Pediatric Neurology. 8: 445-449.
17. Chinnery PF, Turnbull DM. (1998). Vomiting, anorexia, and mitochondrial DNA disease. Lancet. 351: 448.
18. Gerard Y, Maulin L, Yazdanpanah Y, De LT, Amiel C, Maurage CA, Robin S, Sablonniere B, Dhennain C, Mouton Y. (2000). Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS. 14: 2723-2730.
19. Grinspoon S. (2003). Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clinical Infectious Diseases. 37: S85-S90.
20. Grunfeld C, Tien P. (2003). Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clinical Infectious Diseases. 37: S43-S46.
21. Harris M, Tesiorowski A, Montaner J. Screening for nucleoside-associated lactic acidosis. XIIII international AIDS Conference 2000. Abstract
22. Hohorst HJ 1970, in Methoden der enzymatischen analyse, Bergmeyer, ed., verleg Chemie, Weinheim, pp. 1425.
23. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. (2001). Metabolic complications associated with antiretroviral therapy. Antiviral Research. 51: 151-177.
24. John M, Mallal S. (2002). Hyperlactatemia syndromes in people with HIV infection. Currunt Opinion Infectious Diseaes. 15: 23-29.
25. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA. (2001). Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 15: 717-723.
26. John M, Nolan D, Mallal S. (2001). Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy. 6: 9-20.
27. Le Bras P, D'Oiron R, Quertainmont Y, Halfon P, Caquet R. (1994). Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS. 8: 716-717.
28. Lenzo NP, Garas BA, French MA. (1997). Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS. 11: 1294-1296.
29. Lewis W. (2003). Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Research. 58: 189-197.
30. Lewis W, Dalakas MC. (1995). Mitochondrial toxicity of antiviral drugs. Nature Medicine. 1: 417-422.
31. Lonergan JT, Havlir DV, Barber E. Incidence and outcome of hyperlactataemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. 8th Conference on retroviruses and oopportunistic infections. Chicago USA. 2001. Abstract
32. Madias NE. (1986). Lactic acidosis. Kidney International. 29: 752-774.
33. McComsey G. (2002). Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. AIDS Reviews. 4; 140-147.
34. McComsey G, Lonergan JT. (2004). Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management. Journal of Acquired Immune Deficiency Syndrome. 37: S30-S35.
35. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE. (2004). Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clinical Infectious Diseases. 38: 263-270.
36. Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV. (2004). Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clinical Infectious Diseases. 38: S73-S79.
37. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. (2002). Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 16: 1341-1349.
38. Nolan D, Hammond E, James I, McKinnon E, Mallal S. (2003). Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy. 8: 617-626.
39. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang J M, Gastaut JA, Touraine JL. (2000). Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 14: 37-49.
40. Sundar K, Suarez M, Banogon PE, Shapiro JM. (1997). Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Critical Care Medicine. 25: 1425-1430.
41. ter Hofstede HJ, Willems HL, Koopmans PP. (2004). Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. Journal of Clinical Virology. 29: 44-50.
42. van de Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA. (2001), Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 15: 847-855.
43. Vrouenraets SM, Treskes M, Regez RM, Troost N, Smulders YM, Weigel HM, Frissen P H, Brinkman K. (2002). Hyperlactataemia in HIV-infected patients: the role of NRTI-treatinent. Antiviral Therapy. 7: 239-244.
44. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J. (2004). Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology. 39: 311-317.
45. Zaera MG, Miro O, Pedrol E, Soler A, Picon M, Cardellach F, Casademont J, Nunes V. (2001). Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS. 15: 1643-1651.